Stay updated on Safety Tolerability PK of Nintedanib with Pirfenidone in IPF Clinical Trial
Sign up to get notified when there's something new on the Safety Tolerability PK of Nintedanib with Pirfenidone in IPF Clinical Trial page.

Latest updates to the Safety Tolerability PK of Nintedanib with Pirfenidone in IPF Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page now lists updated study locations, adding Connecticut, Louisiana, Minnesota, Missouri, South Carolina, Tennessee, British Columbia, and Manitoba, and includes a revision note (v3.3.3). The previous location sections have been removed, reflecting an update to the location information presented on the page.SummaryDifference0.9%

- Check24 days agoNo Change Detected
- Check45 days agoChange DetectedThe Publications section now states that items are automatically filled from PubMed, and the revision stamp was updated to v3.3.2.SummaryDifference0.1%

- Check52 days agoChange DetectedRemoved the generic government funding/operating status banner from the page. This change does not affect the study details, eligibility criteria, or results.SummaryDifference0.3%

- Check66 days agoChange DetectedNo significant additions or deletions were observed between the two versions of the page; the study details content and layout appear unchanged.SummaryDifference0.3%

- Check95 days agoChange Detected- Added a prominent notice about potential outages due to lapse in government funding and updated operating status guidance. - Updated version from v3.1.0 to v3.2.0.SummaryDifference4%

- Check102 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to Safety Tolerability PK of Nintedanib with Pirfenidone in IPF Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety Tolerability PK of Nintedanib with Pirfenidone in IPF Clinical Trial page.